Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 144510Orphan Drug2 approvals7 trials

GC CELL CORPORATION

Official website

GC Cell develops cell and gene therapies including Immuncell-LC and NK cell therapy pipelines licensed to Artiva Biotherapeutics in the US.

As of 2026-10-10, GC CELL CORPORATION has 1 Korean MFDS drug approval, 12 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2011 and listed on KOSDAQ in 2016, GC Cell originated from the 2011 acquisition of Green Cross's cell therapy business. It develops the liver cancer treatment Immuncell-LC alongside gene-modified NK cell therapies CAR-NK and CAR-T, and also runs specimen testing, cord blood banking, bio-logistics (G-HUB), and CDMO businesses. It has licensed NK cell therapy programs AB-101, AB-201, AB-202, and AB-205 (GCC2005) to Artiva Biotherapeutics in the US, and in September 2024 completed a technology transfer of Immuncell-LC to PT Bifarma Adiluhung in Indonesia.

Products & technology

  • Immuncell-LCLiver cancer (hepatocellular carcinoma) treatment
  • NK/T cell therapies (CAR-NK, CAR-T)Next-generation cell therapies; CD5 CAR-NK targets T-cell blood cancers
  • Specimen testing serviceSpecimen testing for disease diagnosis, prevention, treatment and health assessment
  • Cord blood bank serviceCord blood storage and hematopoietic stem cell services
  • Bio-logistics service (G-HUB)Cold chain transport/storage and integrated logistics management for cell therapies, specimens, and pharmaceuticals
  • CDMO serviceContract development and manufacturing of pharmaceuticals

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2025 / 1 Korean MFDS drug approvals · 2021

  • Orphan자가유래 BCMA 표적 CAR-T 세포치료제2025-07-09
    Orphan Drug designation20250075015
  • MFDS drugImmuncell-LC2021-08-27
    Drug · Prescription · Approval202106211

Clinical trials

data.go.kr

7 MFDS clinical trial authorisations · 2016–2024 (Phase 1 4 · Phase 3 1 · Phase 1/2 1 · Phase 2a 1)

  • Phase 1GCC20052024-08-14

    3 trial sites

  • Phase 1AB-2012023-12-21
  • Phase 1CT3032021-10-19

    3 trial sites

  • Phase 1CT3032021-08-18

    3 trial sites

  • Phase 3이뮨셀엘씨주2020-12-21

    14 trial sites

  • Phase 1/2MG41012018-10-02

    3 trial sites

  • Phase 2aMG41012016-01-11

    6 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 5 more trials

R&D and key agreements

Source: DART corporate disclosure

CD5 CAR-NK · T세포 혈액암 · 임상승인 · Received clinical trial approval as a treatment for T-cell blood cancers with high unmet need.

AB-101 · NK세포치료제 (항체 병용) · 미국 임상 1/2a상 진행 중 · Combination trial with an antibody is ongoing with Artiva Biotherapeutic in the US.

AB-201 · NK세포치료제 · 미국 임상 IND 승인

AB-202 · NK세포치료제 · 미국 임상 IND 준비 중

AB-205(GCC2005) · NK세포치료제 · 한국 임상 1상 진행 중

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 2 more publications

Patents

KIPRIS · applicant-matched
Show 90 more patents

AI reads

MAA server logs · IP-verified
64
Times AI engines pulled GC CELL CORPORATION's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

62
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

14
live 1
Last 7 days
54
live 1
Last 30 days
64
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot54
  • PerplexityPerplexityBot3
  • GoogleGoogleOther2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for GC CELL CORPORATION and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition